Government-Owned Inventions; Availability for Licensing, 51834-51835 [06-7327]
Download as PDF
<![CDATA[
51834
Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices
TABLE A.—ANNUALIZED BURDEN ESTIMATES FOR CHIS 2007 DATA COLLECTION
Estimated
number of
respondents
Data collection
Frequency of
response
Average time
per response
Annual hour
burden
(1) Pilot Test Adult Demographics .................................................................
CCM ...............................................................................................................
(2) Full Survey Adult Demographics ..............................................................
CCM ...............................................................................................................
150
150
55,000
55,000
1
1
1
1
.07
.03
.07
.03
11
5
3,850
1,650
Totals ......................................................................................................
55,150
1
.1
5,516
There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the
proposed performance of the functions
of the agency, including whether the
information shall have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Nancy Breen,
Ph.D., Project Officer, National Cancer
Institute, EPN 4005, 6130 Executive
Boulevard MSC 7344, Bethesda,
Maryland 20852–7344, or call non-toll
free number 301–496–8500 or FAX your
request, including your address to
breenn@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of this
publication.
FOR FURTHER INFORMATION CONTACT:
erjones on PROD1PC72 with NOTICES
Dated: August 24, 2006.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 06–7328 Filed 8–30–06; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:29 Aug 30, 2006
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Novel Acylthiol Compositions and
Methods of Making and Using Them
Description of Technology: This
invention provides a novel family of
acylthiols and uses thereof. More
specifically, this invention provides
effective inhibitors of HIV that
selectively target its highly conserved
nucleocapsid protein (NCp7) by
interacting with metal chelating
structures of a zinc finger-containing
protein. Because of the mutationally
intolerant nature of NCp7, drug
resistance is much less likely to occur
with compounds attacking this target. In
addition, these drugs should inactivate
all types and strains of HIV and could
also inactivate other retroviruses, since
most retroviruses share one or two
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
highly conserved zinc fingers that have
the CCHC motif of the HIV Ncp7.
Finally, this invention could be very
useful for the large-scale practical
synthesis of HIV inhibitors, because
these compounds can be prepared by
using inexpensive starting materials and
facile reactions. Thus, it opens the
possibility that an effective drug
treatment for HIV could be made
available to much larger populations.
These thioesters may also be used as an
active component in topical
applications that serve as a barrier to
HIV infection.
Inventors: John K. Inman (NIAID),
Atul Goel (NCI), Ettore Appella (NCI),
James A. Turpin (NIAID), Marco Schito
(NCI).
Publications:
1. ML Schito, A Goel, Y Song, JK
Inman, RJ Fattah, WG Rice, JA Turpin,
A Sher, E Appella. In vitro antiviral
activity of novel human
immunodeficiency virus type 1
nucleocapsid p7 zinc finger inhibitors
in a transgenic murine model. AIDS Res
Hum Retroviruses. 2003 Feb;19(2):91–
101.
2. P Srivastava, M Schito, RJ Fattah,
T Hara, T Hartman, RW Buckheit Jr, JA
Turpin, JK Inman, E Appella.
Optimization of unique, uncharged
thioesters as inhibitors of HIV
replication. Bioorg Med Chem. 2004 Dec
15;12(24):6437–6450.
3. LM Jenkins, JC Byrd, T Hara, P
Srivastava, SJ Mazu, SJ Stahl, JK Inman,
E Appella, JG Omichinski, P Legault.
Studies on the mechanism of
inactivation of the HIV–1 nucleocapsid
protein NCp7 with 2mercaptobenzamide thioesters. J Med
Chem. 2005 Apr 21;48(8):2847–2858.
4. V Basrur, Y Song, SJ Mazur, Y
Higashimoto, JA Turpin, WG Rice, JK
Inman, E Appella. Inactivation of HIV–
1 nucleocapsid protein P7 by
pyridinioalkanoyl thioesters.
Characterization of reaction products
and proposed mechanism of action. J
Biol Chem. 2000 May 19;275(20):14890–
14897.
5. JA Turpin, Y Song, JK Inman, M
Huang, A Wallqvist, A Maynard, DG
E:\FR\FM\31AUN1.SGM
31AUN1
Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices
Covell, WG Rice, E Appella. Synthesis
and biological properties of novel
pyridinioalkanoyl thiolesters (PATE) as
anti-HIV–1 agents that target the viral
nucleocapsid protein zinc fingers. J Med
Chem. 1999 Jan 14;42(1):67–86.
Patent Status: U.S. Patent Application
No. 10/485,165 filed 28 Jan 2004,
claiming priority to 03 Aug 2001 (HHS
Reference No. E–329–2000/0–US–06).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Sally H. Hu, Ph.D.,
M.B.A.; 301/435–5605;
hus@mail.nih.gov.
Novel Thioesters and Uses Thereof
erjones on PROD1PC72 with NOTICES
Description of Technology: The
human immunodeficiency virus (HIV) is
the causative agent of acquired
immunodeficiency syndrome (AIDS).
Drug-resistance is a critical factor
contributing to the gradual loss of
clinical benefit to treatments for HIV
infection. Accordingly, combination
therapies have further evolved to
address the mutating resistance of HIV.
However, there has been great concern
regarding the apparent growing
resistance of HIV strains to current
therapies.
The present invention provides for a
novel family of thioesters and uses
thereof. These thioesters are capable of
inactivating viruses by a variety of
mechanisms, particularly by
complexing with metal ion-complexing
zinc fingers. The invention further
provides for methods for inactivating a
virus, such as the human
immunodeficiency virus (HIV), using
these compounds, and thereby also
inhibiting transmission of the virus.
Inventors: James A. Turpin (NCI),
Yongsheng Song (NCI), John K. Inman
(NIAID), Mingjun Huang (NCI), Anders
Wallqvist (NCI), David G. Covell (NCI),
William G. Rice (NCI), Ettore Appella
(NCI), et al.
Patent Status: U.S. Patent No.
6,706,729 issued 16 Mar 2004 (HHS
Reference No. E–136–1998/0–US–10);
U.S. Patent Application No. 10/738,062
filed 16 Dec 2003 (HHS Reference No.
E–136–1998/0–US–11).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Sally H. Hu, Ph.D.,
M.B.A.; 301/435–5605;
hus@mail.nih.gov.
Dated: August 25, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–7327 Filed 8–30–06; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:29 Aug 30, 2006
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A Novel Small Protein Antibiotic
Description of Technology: Due to the
increase in drug resistance among
bacteria, continued progress in the
development of new antibiotic
treatments is needed. Available for
licensing and commercial development
is the small protein SrgT, its analogs
and related peptides. SrgT is a 43 amino
acid protein that effectively inhibits
bacterial growth. This protein likely
exerts its antibiotic action by inhibiting
the metabolism of glucose in these
microorganisms. The claimed invention
includes methods for SrgT synthesis
and suggested modifications for
production of SrgT analogs and related
peptides, which may remain effective
against potential SrgT resistant bacteria.
Thus, the current technology provides a
novel approach to the treatment and
prevention of bacterial infections.
Application: Novel therapeutics and
prophylactics for bacterial infections.
Development Status: Preclinical data
is available at this time.
Inventors: Carin K. Vanderpool and
Susan Gottesman (NCI).
Selected Publication: CK Vanderpool,
S Gottesman. Involvement of a novel
transcriptional activator and small RNA
in post-transcriptional regulation of the
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
51835
glucose phosphoenolpyruvate
phosphotransferase system. Mol
Microbiol. 2004 Nov; 54(4):1076–1089.
Patent Status: U.S. Provisional
Application No. 60/799,830 filed 11
May 2006 (HHS Reference No. E–166–
2006/0–US–01).
Licensing Status: Available for nonexclusive and exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301/435–4507; thalhamc@mail.nih.gov.
Methods and Compositions for the
Production of Highly Effective Vaccines
Against Cancers and Infections
Diseases
Description of Technology: Because
cancers and infectious diseases remain
prominent causes of death among adults
and children worldwide, the availability
of vaccines targeting these conditions is
a global health priority. With the current
vaccine development state-of-the-art,
there are limitless combinations of
enhancing molecules that can be used
with antigen vaccines targeting these
diseases. The technology offered for
licensing and commercial development
combines effective aspects of antigenvaccines, including peptides and other
forms of vaccination, with enhancing
molecules, including co-stimulation of
T cell immunity for efficient vaccine
development.
The claimed invention includes a
non-viral polynucleotide vector
encoding immune enhancing molecules,
such as the T cell co-stimulatory
molecule B7.1 (CD80), which
significantly enhance cellular immune
responses when combined with antigen
stimulation. Delivery of this costimulatory molecule as non-replicating
DNA with any antigenic form, peptides
in this case, overcomes the problems of
combining enhancing molecules with
the antigen in the same DNA vector, coinfecting or transfecting these molecules
in the same antigen presenting or tumor
cell, or manufacturing enhancing
molecules in the same format as the
antigens. Furthermore, the use of this
chimeric vaccine with the enhancing
molecule expressed as polynucleotide
vector overcomes the low antigenicity
and safety considerations of viral
vectors, as well as the instability and
conformational maintenance challenges
associated with the use of full-length
protein delivery. Furthermore,
polynucleotide’s constructs encoding
enhancing molecules are inexpensive to
produce and can potentially be used
along with any form of antigen vaccine
delivery system, including peptides,
full-length proteins and naked DNA
antigens.
E:\FR\FM\31AUN1.SGM
31AUN1
]]>Agencies
[Federal Register Volume 71, Number 169 (Thursday, August 31, 2006)]
[Notices]
[Pages 51834-51835]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7327]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Novel Acylthiol Compositions and Methods of Making and Using Them
Description of Technology: This invention provides a novel family
of acylthiols and uses thereof. More specifically, this invention
provides effective inhibitors of HIV that selectively target its highly
conserved nucleocapsid protein (NCp7) by interacting with metal
chelating structures of a zinc finger-containing protein. Because of
the mutationally intolerant nature of NCp7, drug resistance is much
less likely to occur with compounds attacking this target. In addition,
these drugs should inactivate all types and strains of HIV and could
also inactivate other retroviruses, since most retroviruses share one
or two highly conserved zinc fingers that have the CCHC motif of the
HIV Ncp7. Finally, this invention could be very useful for the large-
scale practical synthesis of HIV inhibitors, because these compounds
can be prepared by using inexpensive starting materials and facile
reactions. Thus, it opens the possibility that an effective drug
treatment for HIV could be made available to much larger populations.
These thioesters may also be used as an active component in topical
applications that serve as a barrier to HIV infection.
Inventors: John K. Inman (NIAID), Atul Goel (NCI), Ettore Appella
(NCI), James A. Turpin (NIAID), Marco Schito (NCI).
Publications:
1. ML Schito, A Goel, Y Song, JK Inman, RJ Fattah, WG Rice, JA
Turpin, A Sher, E Appella. In vitro antiviral activity of novel human
immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in
a transgenic murine model. AIDS Res Hum Retroviruses. 2003
Feb;19(2):91-101.
2. P Srivastava, M Schito, RJ Fattah, T Hara, T Hartman, RW
Buckheit Jr, JA Turpin, JK Inman, E Appella. Optimization of unique,
uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem.
2004 Dec 15;12(24):6437-6450.
3. LM Jenkins, JC Byrd, T Hara, P Srivastava, SJ Mazu, SJ Stahl, JK
Inman, E Appella, JG Omichinski, P Legault. Studies on the mechanism of
inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-
mercaptobenzamide thioesters. J Med Chem. 2005 Apr 21;48(8):2847-2858.
4. V Basrur, Y Song, SJ Mazur, Y Higashimoto, JA Turpin, WG Rice,
JK Inman, E Appella. Inactivation of HIV-1 nucleocapsid protein P7 by
pyridinioalkanoyl thioesters. Characterization of reaction products and
proposed mechanism of action. J Biol Chem. 2000 May 19;275(20):14890-
14897.
5. JA Turpin, Y Song, JK Inman, M Huang, A Wallqvist, A Maynard, DG
[[Page 51835]]
Covell, WG Rice, E Appella. Synthesis and biological properties of
novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that
target the viral nucleocapsid protein zinc fingers. J Med Chem. 1999
Jan 14;42(1):67-86.
Patent Status: U.S. Patent Application No. 10/485,165 filed 28 Jan
2004, claiming priority to 03 Aug 2001 (HHS Reference No. E-329-2000/0-
US-06).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435-5605;
hus@mail.nih.gov.
Novel Thioesters and Uses Thereof
Description of Technology: The human immunodeficiency virus (HIV)
is the causative agent of acquired immunodeficiency syndrome (AIDS).
Drug-resistance is a critical factor contributing to the gradual loss
of clinical benefit to treatments for HIV infection. Accordingly,
combination therapies have further evolved to address the mutating
resistance of HIV. However, there has been great concern regarding the
apparent growing resistance of HIV strains to current therapies.
The present invention provides for a novel family of thioesters and
uses thereof. These thioesters are capable of inactivating viruses by a
variety of mechanisms, particularly by complexing with metal ion-
complexing zinc fingers. The invention further provides for methods for
inactivating a virus, such as the human immunodeficiency virus (HIV),
using these compounds, and thereby also inhibiting transmission of the
virus.
Inventors: James A. Turpin (NCI), Yongsheng Song (NCI), John K.
Inman (NIAID), Mingjun Huang (NCI), Anders Wallqvist (NCI), David G.
Covell (NCI), William G. Rice (NCI), Ettore Appella (NCI), et al.
Patent Status: U.S. Patent No. 6,706,729 issued 16 Mar 2004 (HHS
Reference No. E-136-1998/0-US-10); U.S. Patent Application No. 10/
738,062 filed 16 Dec 2003 (HHS Reference No. E-136-1998/0-US-11).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435-5605;
hus@mail.nih.gov.
Dated: August 25, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 06-7327 Filed 8-30-06; 8:45 am]
BILLING CODE 4140-01-P
